HIM
MRSN

Hillsdale Investment Management’s Mersana Therapeutics MRSN Stock Holding History

Hillsdale Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27,728
Closed -$2.85M – 616
2023
Q1 		$2.85M Hold
27,728
– – 0.24% 136
2022
Q4 		$4.06M Buy
27,728
+108
+0.4% +$18.3K 0.34% 113
2022
Q3 		$4.67M Buy
+27,620
New +$4.49M 0.42% 82

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Hillsdale Investment Management's MRSN Position: Q2 2023 in Review

Hillsdale Investment Management sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 27,728 shares — an estimated $2.85M sold.

Hillsdale Investment Management first reported a position in MRSN in Q3 2022 and held it in 3 quarters. The position peaked at $4.67M in Q3 2022. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Hillsdale Investment Management reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 27,728 Mersana Therapeutics shares in Q2 2023, an estimated $2.85M.
  • Hillsdale Investment Management first reported a position in Mersana Therapeutics in Q3 2022 and held it in 3 quarters.
  • Hillsdale Investment Management's Mersana Therapeutics position peaked at $4.67M in Q3 2022.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Hillsdale Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.